# US 2013/0280209 A1 · Method for treating type 1 diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280209 A1
- Document ID: US20130280209A1
- Status: Published application
- Kind: A1
- Application number: 13/862,927
- Filed: 2013-04-15
- Published: 2013-10-24
- Earliest claimed: 2009-03-19
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Lt; Ben-Gurion University of the Negev Research and Development Authority; Hadasit Medical Research Services and Development Ltd.
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Lt; Ben-Gurion University of the Negev Research and Development Authority; Hadasit Medical Research Services and Development Ltd.
- Inventors: Ofer MANDELBOIM; Angel PORGADOR; Yaakov NAPARSTEK; Chamutal GUR
- Web page: https://patentgrep.com/patent/US20130280209A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 37/02: Immunomodulators
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

## Claims

### Claim 1

A method for preventing or treating type 1 diabetes, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising at least one protein and a pharmaceutically acceptable carrier, wherein the protein comprises an isolated fragment of the extracellular region of NKp46, thereby preventing or treating type 1 diabetes in the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the type 1 diabetes is immune-mediated diabetes.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the NKp46 is human NKp46.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the isolated fragment of the extracellular region of NKp46 comprises the D2 domain or a fragment thereof and optionally further comprises a fragment of the D1 domain.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the isolated fragment is substantially devoid of the D1 domain.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the D2 domain is selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 9 and SEQ ID NO: 10.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the isolated fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-10.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the isolated fragment comprises a D2 domain variant and wherein the variant comprises at least one amino acid substitution in the D2 domain.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the at least one amino acid substitution is at a residue selected from the group consisting of threonine 125, threonine 225, lysine 157, lysine 170, arginine 160, arginine 166, histidine 163, asparagine 216, and a combination thereof, where the numbers correspond to the residue positions of SEQ ID NO: 29, or wherein the at least one amino acid substitution is selected from the group consisting of T125A; T225A; T225S; T225N; N216A; K157Q; R160Q; H163Q; R166Q; K170T and a combination thereof, where the numbers correspond to the residue positions of NKp46 of SEQ ID NO: 29.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the D2 domain variant is selected from the group consisting of SEQ ID NOs: 12-16.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the protein comprising an isolated fragment of the extracellular region of NKp46 is selected from the group consisting of a fusion protein and a protein conjugate.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the fusion protein comprises a first segment and a second segment, wherein the first segment comprises the D2 domain or a fragment thereof, and wherein the second segment comprises at least one heterologous protein selected from the group consisting of an immunoglobulin, a cytokine, an immunomodulatory protein or peptide, an NK receptor other than NKp46, a hormone, a growth factor and fragments thereof.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the heterologous protein is an immunoglobulin fragment or wherein the heterologous protein is the Fc region of IgG1.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 17-22.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the fusion protein comprises a D2 domain variant as the first segment and the Fc region of IgG1 as the second segment, wherein the D2 domain variant comprises at least one amino acid substitution in the D2 domain at a residue selected from the group consisting of threonine 125, threonine 225, lysine 157, lysine 170, arginine 160, arginine 166, histidine 163, asparagine 216, and a combination thereof, where the numbers correspond to the residue positions of SEQ ID NO: 29.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the first segment comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 12-16.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the cytokine is selected from the group consisting of IL-2, IL-4 and IL-10; or wherein the immunomodulatory protein or peptide is selected from the group consisting of heat shock protein 60 (HSP60) or a fragment thereof, roquinimex, Q fever complement-fixing antigen (QFA), anti-CD3 antibody and a combination thereof; or wherein the NK receptor other than NKp46 is NKG2D; or wherein the hormone is selected from the group consisting of insulin, glucagon and a combination thereof.

### Claim 18 (depends on 2)

The method according to claim 2, comprising administering the composition at a stage of type 1 diabetes selected from the group consisting of pre-insulitis, early insulitis, pre-diabetes, overt diabetes and a combination thereof.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the administering is carried out by a route selected from the group consisting of parenteral, oral, transdermal and topical.

### Claim 20 (depends on 1)

The method according to claim 1, further comprising administering at least one immunostimulatory agent in conjunction with administering the composition.
